scholarly article | Q13442814 |
P50 | author | Nicholas J. Short | Q42365103 |
Rashmi Kanagal-shamanna | Q43140093 | ||
Sanam Loghavi | Q43242254 | ||
Jorge Eduardo Cortes | Q60320900 | ||
Hagop Kantarjian | Q60394812 | ||
Courtney D DiNardo | Q60964369 | ||
Zeev Estrov | Q64026337 | ||
Guillermo Garcia-Manero | Q66385413 | ||
Xuelin Huang | Q87045391 | ||
Abhishek Maiti | Q87632566 | ||
Elias J Jabbour | Q87641766 | ||
Naveen Pemmaraju | Q87733857 | ||
Prithviraj Bose | Q88053364 | ||
Gautam Borthakur | Q88200100 | ||
Naval Daver | Q88327648 | ||
Tapan M Kadia | Q88337925 | ||
Marina Konopleva | Q89564940 | ||
Steven M Kornblau | Q89882472 | ||
Maro Ohanian | Q90322123 | ||
Christopher B Benton | Q90558065 | ||
Mary Ann Richie | Q114427944 | ||
P2093 | author name string | Wei Qiao | |
Nitin Jain | |||
Farhad Ravandi | |||
Sherry Pierce | |||
Yesid Alvarado | |||
Yvonne Gasior | |||
P2860 | cites work | Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine | Q27853006 |
Acute Myeloid Leukemia | Q28267442 | ||
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia | Q33401766 | ||
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia | Q33702409 | ||
Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features | Q33782633 | ||
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine | Q33841988 | ||
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients | Q34398397 | ||
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations | Q35126237 | ||
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. | Q35486110 | ||
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts | Q35859212 | ||
TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. | Q35921904 | ||
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia | Q36208652 | ||
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia | Q36781942 | ||
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents | Q37046564 | ||
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia | Q37462852 | ||
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes | Q37566878 | ||
Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring | Q37618897 | ||
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia | Q37635209 | ||
Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome | Q37688233 | ||
Acute myeloid leukemia and myelodysplastic syndromes in older adults | Q38234863 | ||
Selecting initial treatment of acute myeloid leukaemia in older adults | Q38981876 | ||
TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes | Q39555179 | ||
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | Q40543180 | ||
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies | Q44646952 | ||
Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis | Q46117117 | ||
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens | Q46317683 | ||
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study | Q47655563 | ||
Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. | Q50859525 | ||
Molecular Minimal Residual Disease in Acute Myeloid Leukemia | Q57201597 | ||
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome | Q82366072 | ||
Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy | Q86562578 | ||
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort | Q88446399 | ||
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia | Q88493206 | ||
P433 | issue | 1 | |
P921 | main subject | phase II clinical trial | Q42824440 |
P304 | page(s) | e29-e37 | |
P577 | publication date | 2018-12-10 | |
P1433 | published in | The Lancet. Haematology. | Q26840042 |
P1476 | title | Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial | |
P478 | volume | 6 |